Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16010483 | 0.92 | GPR55 (0.45) | GPR55CYP3A4ACHECHRM1ALOX15 | |
| SCHEMBL16009497 | 0.90 | GPR55 (0.44) | GPR55CYP3A4ACHECHRM1ALOX15 | |
| SCHEMBL29446963 | 0.90 | GPR55 (0.44) | GPR55CYP3A4ACHECHRM1ALOX15 | |
| SCHEMBL16018035 | 0.89 | CYP3A4 (0.44) | GPR55CYP3A4ACHECHRM1ALOX15 | |
| SCHEMBL2048645 | 0.83 | SELL (0.42) | GPR55ACHEHTR2BPTPN1TDP1 | |
| SCHEMBL16018021 | 0.80 | CHRM1 (0.41) | GPR55CYP3A4ACHECHRM1ALOX15 | |
| SCHEMBL24652323 | 0.79 | CYP3A4 (0.46) | GPR55CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL25164854 | 0.79 | CYP3A4 (0.37) | GPR55CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL3133781 | 0.78 | CHRM1 (0.39) | GPR55CYP3A4CHRM1ALOX15MAOA | |
| SCHEMBL11701041 | 0.75 | CNR1 (0.41) | ACHECHRM1TBXA2RADRA1ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10470986-B2 | Resorcinol compounds for dermatological use | CONOPCO, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-B1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER PLC A COMPANY REGISTERED IN ENGLAND AND WALES UNDER COMPANY NO 41424 OF (GB) | 2018-02-14 | — | — | EP | disclosed |
| EP-2964182-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | Unilever PLC, a company registered in England and Wales under company no. 41424 of (GB) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | CONOPCO, INC., D/B/A UNILEVER (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138471-A2 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | AMPERE LIFE SCIENCES, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | UNILEVER N.V. (NL) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000669-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | GPR55 3560/4885CYP3A4 1742/4885ACHE 1186/4885 |
| US-20140256830-A1 | RESORCINOL COMPOUNDS FOR DERMATOLOGICAL USE | NQO1, RBP4, KEAP1 | GPR55 3560/4885CYP3A4 1742/4885ACHE 1186/4885 |
| US-10470986-B2 | Resorcinol compounds for dermatological use | NQO1, RBP4, KEAP1 | GPR55 3560/4885CYP3A4 1742/4885ACHE 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.